12:00 AM
 | 
May 27, 2013
 |  BC Week In Review  |  Company News  |  Deals

KineMed, AstraZeneca deal

KineMed partnered with AstraZeneca's MedImmune LLC unit to study how an undisclosed mAb affects the dynamics of the cellular prion protein ( PRNP; PrP;

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >